In India’s ongoing battle against cancer, the introduction of advanced therapies marks a significant milestone. The government’s recent decision to eliminate customs duties and reduce the Goods and Services Tax (GST) on three groundbreaking anti-cancer drugs—Trastuzumab Deruxtecan (Enhertu), Osimertinib (Tagrisso), and Durvalumab (Imfinzi)—aims to improve access to these life-saving treatments for patients who need them most. This article delves into the science behind these therapies, the cancers they target, and the hope they represent for many Indian patients.
Understanding the Therapies
- Trastuzumab Deruxtecan (Enhertu):
- Type: Antibody-Drug Conjugate (ADC)
- Mechanism: Enhertu combines a targeted antibody that recognizes the HER2 protein on cancer cells with a potent chemotherapy drug. This enables precise delivery of the chemotherapy directly to the cancer cells, minimizing damage to healthy tissue.
- Target Cancers: Enhance is primarily approved for HER2-positive breast and gastric cancers. These forms of cancer are characterized by overexpression of the HER2 protein, leading to more aggressive disease progression.
- Advancement: This therapy represents a significant step forward in oncology because it harnesses the body’s immune system to target cancer cells more effectively, improving outcomes for patients who previously had limited treatment options.
- Osimertinib (Tagrisso):
- Type: Tyrosine Kinase Inhibitor (TKI)
- Mechanism: Tagrisso specifically targets mutations in the EGFR gene that are common in non-small cell lung cancer (NSCLC). By inhibiting the activity of this mutation, it disrupts cancer cell growth and survival.
- Target Cancers: This medication is specifically indicated for patients with EGFR-positive lung cancer, which is one of the most prevalent types of cancer in India.
- Advancement: Osimertinib is a breakthrough in targeted therapy, providing an option for patients who display resistance to other EGFR inhibitors. It has consistently improved survival rates and decreased side effects compared to earlier-generation therapies.
- Durvalumab (Imfinzi):
- Type: Immunotherapy
- Mechanism: Imfinzi works by inhibiting the PD-L1 protein, a mechanism cancer cells exploit to evade an immune response. By blocking this interaction, Durvalumab helps to reactivate the immune system, allowing it to detect and fight cancer cells more effectively.
- Target Cancers: This therapy is primarily approved for patients with unresectable stage III non-small cell lung cancer and for various cancers related to the PD-L1 protein, including bladder and biliary tract cancers.
- Advancement: By utilizing the body’s immune system, immunotherapy has transformed cancer treatment paradigms, offering renewed hope to patients with otherwise limited treatment options.
Impact on Patients and the Healthcare Landscape
The introduction of these therapies is a remarkable leap towards improving cancer care in India, especially considering the financial burdens associated with cancer treatment. The recent tax cuts have led to reductions in Maximum Retail Prices (MRPs) for these medications, making them slightly more affordable for patients. However, the base prices still remain prohibitively high, and comprehensive access is hindered by factors such as the necessity of biomarker testing and uneven distribution of healthcare resources across urban and rural areas,.
Who Stands to Benefit?
The patients most likely to benefit from these advanced therapies include those diagnosed with:
- HER2-positive breast or gastric cancers (Enhertu)
- EGFR-positive lung cancers (Tagrisso)
- PD-L1 expressing cancers such as lung, bladder, and biliary tract (Imfinzi)
While these advancements offer significant hope, challenges remain regarding access and systemic barriers within India’s healthcare system. Patient advocacy groups urge for broader action, advocating for the inclusion of more medications and improvements in diagnostic infrastructure, aiming to ensure that all patients can benefit from these life-saving therapies,.
As India faces a burgeoning cancer crisis—with 1.46 million new cases diagnosed annually—the increased accessibility to advanced treatments like Enhertu, Tagrisso, and Imfinzi is a pivotal moment in the fight against cancer. These therapies not only exemplify cutting-edge advancements in oncology but also highlight the ongoing need for comprehensive healthcare reforms to truly achieve equitable access for all patients in need. The journey continues, but with these game-changing therapies, there is renewed optimism in the fight against cancer in India.
–Srikanth Amirapu
